Samsung Biologics signed a $242 million contract manufacturing organization (CMO) deal with global pharmaceutical giant Bristol-Myers Squibb for the production of immuno-oncology drugs, the drug manufacturer said Monday. Samsung said the production agreement was made with BMS subsidiary Swords Laboratories. Under the contract, its Plant 4 will serve as the production base for BMS flagship immuno-oncology product for the next seven years through 2030.
Samsung Biologics signed two biosimilar product-manufacturing contracts with global pharmaceutical company Pfizer, totaling $897 million, demonstrating the growing reputation of the Korean contract-based drug manufacturer, the company said Tuesday.
EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.